Many patients can safely continue GLP-1 medications with appropriate precautions, but the decision depends on individual risk factors including dose escalation status, gastrointestinal symptoms, and type of surgery
The main difference between dark and light cells was the greater density of the cytoplasm, nuclei, and matrix of the microvilli in the dark cells
The medication works by: Enhancing insulin secretion in a glucose-dependent manner, reducing the risk of hypoglycemia Suppressing glucagon release when blood glucose levels are elevated Slowing gastric emptying , which prolongs satiety and reduces appetite Acting on central appetite regulation in the hypothalamus to decrease food intake Zepbound is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and gradually titrated upward (5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maximum of 15 mg) based on individual tolerance and therapeutic response
Gibbs, J., Young, R
"Did I hit a plateau on GLP-1?" Weight loss on GLP-1 medications sometimes slows down after the first months
